Should I Buy CNTY? CNTY 2026 Analysis

Should You Buy Century Casinos Inc (CNTY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.530

1 Day change

-1.92%

52 Week Range

3.260

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price action and momentum are still bearish, and there’s no near-term catalyst from news/positioning to justify chasing an entry.
Downtrend remains intact (bearish moving-average stack + weakening MACD), so the path of least resistance is still lower despite being near support.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating persistent downside pressure across long/medium/short horizons.
Momentum: MACD histogram -0.0137 and negatively expanding → bearish momentum is strengthening, not reversing.
RSI(6): 31.41 (borderline oversold/low) → a bounce is possible, but not confirmed.
Key levels: Support S1=1.511 then S2=1.476; Resistance Pivot=1.569 then R1=1.626. With price ~1.50, it’s sitting on/just below first support—break risk remains.
Pattern-based projection provided: modest positive bias over 1W/1M, but it conflicts with current momentum/MA structure (treat as lower confidence versus live indicators).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest is extremely call-heavy (OI put/call 0.05; calls 1877 vs puts 90), typically a bullish/optimistic tilt.
Activity: Today’s options volume is 0 (no real-time participation), so sentiment from actual trading flow is not supportive/confirmatory.
Volatility: 30D IV ~72.6 vs HV ~70.2 (close), IV percentile 44.4 and IV rank 9.12 → not a “panic-high” IV environment; options aren’t screaming capitulation.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical mean-reversion potential: RSI near oversold and price is near S1/S2 supports, which can spark short bounces.
- Options open interest skew is call-heavy, suggesting some investors are positioned for upside.
- Financial trend (2025/Q3): losses narrowed YoY (EPS and net loss improved), which is directionally positive if it continues.

Neutral/Negative Catalysts

- Clear bearish technical structure (bearish MA stack + MACD deterioration) suggests downside continuation risk outweighs bounce odds right now.
- No news in the past week → no obvious event-driven catalyst to reverse sentiment quickly.
- Revenue contraction in 2025/Q3 (-1.27% YoY) and gross margin decline (down 2.01% YoY) point to operating headwinds.
- Options have zero volume today → call-heavy OI may be stale positioning rather than fresh bullish conviction.
- No notable insider/hedge fund accumulation signals (both described as neutral).

Financial Performance

Latest quarter: 2025/Q3
Revenue: 153.724M, down 1.27% YoY → slight top-line contraction.
Net income: -10.548M, improved 29.92% YoY (still a loss, but narrowing).
EPS: -0.35, improved 34.62% YoY.
Gross margin: 37.07%, down 2.01% YoY → profitability pressure despite narrower losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst updates are mixed and somewhat unreliable due to ticker/name confusion in the feed:
- Century Casinos (relevant): Stifel (2025-11-12) lowered PT to $3 from $4, maintained Buy, citing slower improvement assumptions.
- Two newer notes appear to reference “Century Therapeutics” (likely not Century Casinos), despite using CNTY in the text—treat those PTs/ratings as potentially misattributed.
Net takeaway (Wall St “pros/cons”):
- Pros: at least one maintained Buy with PT still well above current price; improving loss metrics could support a turnaround narrative.
- Cons: PT cuts indicate tempered expectations; operational metrics (revenue/margin) are not yet clearly improving; lack of fresh catalysts/newsflow.

2 Analyst Rating

Wall Street analysts forecast CNTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTY is 4 USD with a low forecast of 4 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.560

Low

Averages

High

Current: 1.560

Low

Averages

High

Piper Sandler

NULL

Overweight

upgrade

$2 -> $4

AI Analysis

2026-01-20

Reason

Piper Sandler

Price Target

$2 -> $4

AI Analysis

2026-01-20

upgrade

NULL

Overweight

Reason

Piper Sandler raised the firm's price target on Century Therapeutics to $4 from $2 and keeps an Overweight rating on the shares. The firm notes Century plans to submit an IND for CNTY-813 this year and report initial data in 2027. Piper estimates Century now hold pro forma cash of about $267M to fund operations into Q1 2029.

Clear Street

Bill Maughan

Buy

downgrade

2026-01-08

Reason

Clear Street

Bill Maughan

Price Target

2026-01-08

downgrade

Buy

Reason

Clear Street analyst Bill Maughan lowered the firm's price target on Century Therapeutics to $6.60 from $8 and keeps a Buy rating on the shares. The private placement brings the runway out to 1Q29, allowing for development of a fuller picture of the true potential of lead asset CNTY-813 before needing additional capital, the analyst tells investors in a research note. The firm added that it is reducing its price target on dilution from the raise, offset by increased pipeline likelihood of success and peak sales.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNTY

Unlock Now

CNTY Should I Buy

CNTY Should I Buy

Should You Buy Century Casinos Inc (CNTY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch